Group 1 - The three major indices collectively rose, with the medical equipment sector showing active performance, as evidenced by the CSI All Index Medical Care Equipment and Services Index (H30178) increasing by 0.53% [1] - Notable performers within the index included Tianzhihang, which rose over 14%, Shuoshi Bio, which increased over 9%, and Sanyou Medical, which saw a rise of over 6% [1] - The Medical Equipment ETF (159873) recorded a trading volume exceeding 16 million yuan, with a subscription of 5 million units during the trading session [1] Group 2 - The Medical Equipment ETF has experienced a net inflow of funds for nine consecutive trading days, accumulating a total net inflow of 117 million yuan as of January 20 [1] - The ETF's scale has doubled over the past 20 days, reaching a latest circulating scale of 233 million yuan [1] - The ETF closely tracks the CSI All Index Medical Care Equipment and Services Index, which selects listed companies in the medical care theme to reflect the overall performance of these securities [1] Group 3 - The first human subject implanted with Neuralink's brain-machine interface, Nolan Arbo, reported that the module in his brain can be wirelessly upgraded remotely, similar to Tesla's OTA updates [2] - This marks a historic first where a human brain can be updated without surgery, allowing for performance improvements through software updates [2] - Merge Labs, a Silicon Valley startup, has raised $252 million in seed funding from investors including OpenAI, indicating strong interest in advancements in medical technology [2] Group 4 - Guotai Junan Securities noted that the scale of medical equipment bidding continues to grow, supported by ongoing implementation of equipment upgrade policies, which are expected to drive long-term procurement levels [2] - The report recommends medical equipment companies that are likely to benefit from the performance recovery driven by the implementation of these upgrade policies [2]

Core Viewpoint - The company, Shuoshi Biotechnology, has indicated that a portion of its products is exported to EU countries, with sales primarily conducted through domestic entities directly exporting to EU clients. However, the revenue from this business segment constitutes a small proportion of the company's total operating income [1]. Group 1 - The company exports some products to EU countries [1] - Sales are mainly conducted by domestic entities directly exporting to EU clients [1] - Revenue from this business segment is a small proportion of total operating income [1]

Group 1 - The company has reached an agreement with its debtor, Urumqi Rongxin Kanda Trading Co., Ltd., to settle outstanding accounts receivable amounting to RMB 609.94 million, which is part of a total receivable of RMB 692.05 million that has aged over five years [2][3] - The debtor is required to make the payment by January 20, 2026, and failure to do so will allow the company to claim the original debt amount along with a 20% penalty and all costs incurred in recovering the debt [2] - The recovery of this accounts receivable and the reversal of the corresponding bad debt provision is expected to positively impact the company's financial condition and operating results for the year 2026, with the exact impact to be confirmed by the annual audit [4] Group 2 - The company has fully settled the debt relationship with the debtor as of the announcement date, confirming that the payment of RMB 609.94 million has been received in full [3] - The reversal of the bad debt provision adheres to the relevant accounting standards and regulations, ensuring that it does not harm the interests of the company and its shareholders [4]

Core Viewpoint - Shuoshi Bio (688399) has successfully resolved a long-standing accounts receivable issue with Urumqi Rongxin Kangda Trading Co., Ltd, resulting in a positive impact on the company's financial status for 2026 [1] Group 1: Accounts Receivable Situation - The company reported an accounts receivable balance of 6.9205 million yuan from a business collaboration with Urumqi Rongxin Kangda Trading Co., Ltd as of December 31, 2025 [1] - The accounts receivable has aged over five years, and the company has made multiple attempts to collect the debt through communication, legal letters, and lawsuits, but the debtor failed to fulfill repayment obligations [1] - The company has fully provisioned for the bad debt in accordance with accounting standards, which has been reflected in the financial statements for the relevant periods [1] Group 2: Debt Settlement Agreement - The company has actively pursued debt collection and reached a settlement agreement with the debtor, stipulating that the debtor will pay 6.0994 million yuan by January 20, 2026, as full settlement of the 6.9205 million yuan accounts receivable [1] - As of the announcement date, the debtor has fully paid the agreed amount of 6.0994 million yuan, and the debt relationship has been completely settled [1] - The recovery of this accounts receivable and the reversal of the previously provisioned bad debt is expected to have a positive impact on the company's financial condition and operating results for the year 2026 [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、应收账款基本情况 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2020 年度与乌鲁 木齐融信康达商贸有限公司（以下简称"欠款方"）开展试剂销售等业务合作。 截至 2025 年 12 月 31 日，双方往来形成应收账款余额合计人民币 692.05 万元。 该笔应收账款账龄已超 5 年，公司期间已通过多次专人沟通、法律函件、提起诉 讼等方式进行催缴，欠款方未能按期履行还款义务。 根据《企业会计准则》及公司会计政策相关规定，公司已对该笔应收账款全 额计提坏账准备，相关会计处理已计入对应会计期间的财务报表。 二、回款情况 为有效化解上述应收账款回收风险，保障公司及全体股东利益，公司积极推 进催收工作，经与欠款方多次协商，于近期达成债务清偿一致意见并签署协议。 协议约定，欠款方应于 2026 年 1 月 20 日前向公司支付人民币 609.94 万元，视 为该笔 692.05 万元应收账款的全部清偿款项，若欠款方未按上述期限足额支付 款项，公司有权按照原债权金额主张权益，并 ...

Group 1 - The stock price of Shuoshi Bio (688399) closed at 79.98 yuan on January 9, 2026, representing a 16.76% increase from the previous week's price of 68.5 yuan [1] - The company reached a nearly one-year high with an intraday peak of 82.0 yuan on January 9, 2026, and a low of 67.29 yuan on January 6, 2026 [1] - Shuoshi Bio's current total market capitalization is 6.708 billion yuan, ranking 58th out of 127 in the medical device sector and 2801st out of 5182 in the A-share market [1] Group 2 - Shuoshi Bio received a government subsidy of 1.63 million yuan, which is related to income and will impact the company's profit and loss for the fiscal year 2025 [1][3] - The company held its first temporary shareholders' meeting of 2026 on January 5, 2026, where shareholders approved an amendment to increase the company's business scope [2] - A total of 76 shareholders attended the meeting, representing 41.8196% of the total voting rights, with 99.9270% voting in favor of the resolution [2][3]

Group 1 - The core point of the article is that Shuoshi Biotechnology has responded to investor inquiries, indicating that as of December 31, 2025, the total number of shareholders will be 7,302 [1]

Core Insights - The medical device sector experienced a rise of 1.14% on January 8, with Kangtong Medical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Medical Device Sector Performance - Kangtong Medical (301515) closed at 25.48, up 20.02% with a trading volume of 123,300 shares and a transaction value of 291 million [1] - Yuanpeng Medical (300753) closed at 42.62, up 19.99% with a trading volume of 471,600 shares and a transaction value of 1.884 billion [1] - Kefu Medical (301087) closed at 54.00, up 13.52% with a trading volume of 174,300 shares and a transaction value of 92.86 million [1] - Shuoshi Biology (688399) closed at 77.21, up 13.31% with a trading volume of 73,500 shares and a transaction value of 550 million [1] - Anbiping (688393) closed at 27.60, up 6.73% with a trading volume of 69,500 shares and a transaction value of 189 million [1] Capital Flow Analysis - The medical device sector saw a net inflow of 533 million from institutional investors, while retail investors experienced a net outflow of 450 million [2][3] - Yuanpeng Medical had a net inflow of 225 million from institutional investors, but a net outflow of 103 million from retail investors [3] - Lepu Medical (300003) had a net inflow of 181 million from institutional investors, with a net outflow of 67.8 million from retail investors [3]

Group 1 - The Shanghai Composite Index closed at 4089.45 points, above the five-day moving average, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 1,781.548 billion yuan [1] - A total of 658 A-shares have prices that surpassed the five-day moving average, with notable stocks including Zhongcheng Technology, Gangtong Medical, and Shuoshi Biology, showing divergence rates of 15.86%, 14.00%, and 8.74% respectively [1] Group 2 - Stocks with significant divergence rates include: - Zhongcheng Technology (22.67% increase, 15.86% divergence) - Gangtong Medical (20.02% increase, 14.00% divergence) - Shuoshi Biology (11.51% increase, 8.74% divergence) [1] - Other stocks with smaller divergence rates that just crossed the five-day moving average include: - Jialiqi, *ST Zhisheng, and Senyuan Shares [1]

Group 1 - The core viewpoint of the news highlights a strong performance in the medical device sector, particularly with the medical device ETF (159883) showing significant gains and attracting substantial capital inflow [1][4] - The medical device index (H30217) rose by 1.81%, with notable individual stock performances such as Kewei Medical (301087) increasing over 17% and Shuoshi Bio (688399) rising over 12% [1][3] - The medical device ETF has seen a net inflow of 9.32 billion yuan over the past three days, with a peak single-day inflow of 517 million yuan, indicating strong investor interest [1][4] Group 2 - Kewei Medical has made strategic investments in the brain-computer interface sector, including a 5.83% stake in Nulingke Medical, which focuses on implantable brain-computer interface technology [3][4] - The domestic brain-computer interface sector is experiencing significant growth, with a recent unicorn company completing approximately 2 billion yuan in financing, marking it as the second-largest financing in the field globally [4] - The medical device ETF (159883) is the largest in the market, with over 23% exposure to brain-computer interface stocks, and is expected to benefit from domestic innovation and technological advancements [4][5]